Delcath Q1 revenue surges to $19.8M, posts net income of $1.1M vs loss a year ago

DELCATH SYSTEMS, INC.

2025-Q1 EPS reported $0.03 revenue$19,784,000

Total revenue $19.8M (vs $3.1M Q1 2024); HEPZATO KIT sales $18.0M, CHEMOSAT $1.8M.
Net income $1.1M vs net loss of $11.1M in prior-year quarter; gross margin 86%.
Non-GAAP adjusted EBITDA $7.6M vs loss of $7.3M in Q1 2024.
Cash and investments $58.9M, no debt; exercise of Series F warrants added $16.2M.
19 active U.S. centers; FDA cleared IND for phase 2 HEPZATO in metastatic breast cancer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.